



**For Immediate Release**

**Vaxart to Present at the 14<sup>th</sup> Annual Needham Healthcare Conference  
in New York City on Tuesday, April 14, 2015**

**SOUTH SAN FRANCISCO, Calif., April 7, 2015** — Vaxart, Inc., a privately held, clinical-stage company developing vaccines that are administered by tablet rather than by injection, today announced that CEO Wouter Latour, MD, will present a corporate overview at the 14th Annual Needham Healthcare Conference on Tuesday, April 14, 2015 at 3:20 p.m. EDT. The event will be held at the Westin Grand Central Hotel in New York City. Dr. Latour and Vaxart CFO John Harland will also be available to participate in one-on-one meetings with registered attendees.

**About Vaxart**

Vaxart is a privately held company developing oral recombinant vaccines based on its proprietary delivery platform. The Vaxart platform is suitable for delivering any protein antigen such as those used in currently marketed influenza, hepatitis B and human papilloma virus (HPV) vaccines. By eliminating needles, Vaxart's temperature-stable tablet vaccines offer a wide range of advantages such as: convenience, acceptance, self-administration, reduced cold chain requirements, reduced medical waste, and rapid and scalable manufacturing. For more information, please visit [www.vaxart.com](http://www.vaxart.com).

###

**CONTACT:**

Kimberly Minarovich

Burns McClellan

212-213-0006

[kminarovich@burnsmc.com](mailto:kminarovich@burnsmc.com)